Piramal Healthcare is trading higher by 1.7%, or Rs 5, at Rs 366 after the company announced settlement of patent litigation with Baxter Healthcare related to generic version of Suprane (Desflurane).
"Under the settlement, Piramal has obtained a licence to the Baxter patent at issue in the lawsuit pursuant to which the parties agree that Piramal may launch generic Desflurane product in the USA not before than January 2014 subject to US regulatory approval," the company said in a press release.
"The company has agreed not to make, use, sell or offer for sale in the United States, or import into the United States, this product prior to January 2014," the release added.
The stock opened at Rs 360 and touched the high of Rs 370. As many as 4,083 shares have changed hands compared to its two week average of 8,594.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app